We developed in silico neoantigen prediction workflows, VACINUSpMHC and VACINUSTCR, to predict tumor neoantigens more accurately from raw sequencing data based on peptide-MHC binding and a putative tumor-reactive tumor-infiltrating lymphocyte (TIL) TCR-pMHC ternary complex, respectively. This evidence concerns the gene HLA-C and neoplasm.